Trial Profile
A Phase 2a, Randomized, Partially-blind, Placebocontrolled Study to Assess the Efficacy, Safety, and Pharmacokinetics of Treatment With Multiple Doses of JNJ-56136379 as Monotherapy and in Combination With a Nucleos(t)ide Analog in Subjects With Chronic Hepatitis B Virus Infection
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Aug 2023
Price :
$35
*
At a glance
- Drugs Bersacapavir (Primary) ; Entecavir; Tenofovir disoproxil fumarate
- Indications Hepatitis B
- Focus Therapeutic Use
- Acronyms JADE
- Sponsors Janssen Pharmaceutical KK; Janssen Sciences Ireland UC
- 01 Aug 2023 Results assessing Viral sequence analysis of chronic hepatitis B patients treated with the capsid assembly modulator JNJ-56136379 published in the Antiviral Research
- 25 Jan 2023 Final Results published in the Gut
- 02 Sep 2020 Status changed from active, no longer recruiting to completed.